Table 2.
Characteristics of diabetic patients treated with anti-VEGF agents.
| Rapid-Response to anti-VEGF (n = 11) | Slow-Response to anti-VEGF (n = 11) | Non-Response to anti-VEGF (n = 9) | p-Value | |
|---|---|---|---|---|
| Gender (M/F) | 6/5 | 6/5 | 7/2 | n.s. |
| Age (years) | 67.5 ± 9.7 | 71 ± 6.9 | 68.1 ± 11.6 | n.s. |
| Diabetes duration (years) | 12.7 ± 2.6 | 12.9 ± 2.6 | 11.6 ± 2.9 | n.s. |
| HbA1c (%) | 7.75 ± 1.34 | 7.54 ± 1.11 | 7.84 ± 1.3 | n.s. |
| Insulin treatment (%) | 70 | 81.8 | 33.3 | n.s. |
| Phakic status (%) | n.s. | |||
| No cataract | 4 | 2 | 5 | |
| Cataract | 0 | 1 | 0 | |
| Previous cataract surgery | 6 | 8 | 4 | |
| Glaucoma (%) | 10 | 27.3 | 33.3 | n.s. |
| NPDR (%) / PDR (%) | 91 / 9 | 82/18 | 89/11 | n.s. |
| Central Retinal Thickness (µm) | 443 ± 91 | 542 ± 179 | 449 ± 67 | n.s. |
| Macular volume (mm3) | 9.67 ± 1.83 | 11.55 ± 4.16 | 9.62 ± 1.37 | n.s. |
| Mean BCVA (ETDRS letters) | 65 (20/50) | 67.2 (20/50) | 62.5 (20/63) | n.s. |
VEGF: Vascular Endothelial Growth Factor; M/F: Male, female; NPDR: non-proliferative diabetic retinopathy; PDR: proliferative diabetic retinopathy. BCVA: best corrected visual acuity. ETDRS: Early Treatment Diabetic Retinopathy Study.